[
  {
    "objectID": "quarto/index.html",
    "href": "quarto/index.html",
    "title": "The Impact of Body Mass Index on Mortality in Patients Hospitalized with Atrial Fibrillation: Insights from the National Inpatient Sample",
    "section": "",
    "text": "Reference Papers:\n\nBhonsale et al. (2024)\n\nStudy Objective: Investigate the influence of body mass index (BMI) on inpatient admissions with a history of atrial fibrillation (A-Fib).\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with an ICD-10 diagnosis code for BMI and A-Fib.\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($) [adjusted to 2020 dollars, using CPI data by the U.S. Bureau of Labor Statistics]\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of BMI on outcomes, adjusted for:\n\nDemographics: Age, sex, race, insurance, residential income, residential region, hospital location/teaching status, and hospital census region.\nMedical History: Atrial fibrillation present.\nComorbidities: Charlson comorbidity index, cancer, coronary artery disease, cerebrovascular disease, heart failure, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, hyperlipidemia, liver disease, peripheral vascular disease, sleep apnea, valvular heart disease, alcohol use, and smoking status.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#preamble",
    "href": "quarto/index.html#preamble",
    "title": "The Impact of Body Mass Index on Mortality in Patients Hospitalized with Atrial Fibrillation: Insights from the National Inpatient Sample",
    "section": "",
    "text": "Reference Papers:\n\nBhonsale et al. (2024)\n\nStudy Objective: Investigate the influence of body mass index (BMI) on inpatient admissions with a history of atrial fibrillation (A-Fib).\nData Source: Cross-sectional analysis of the National Inpatient Sample (NIS) from 2018 to 2020.\nPatient Selection: Included all inpatient admissions with an ICD-10 diagnosis code for BMI and A-Fib.\nPrimary Outcomes:\n\nIn-hospital all-cause mortality\nTotal hospital length of stay (days)\nTotal charge, inflation adjusted to 2020 ($) [adjusted to 2020 dollars, using CPI data by the U.S. Bureau of Labor Statistics]\n\nStatistical Analysis: Multiple logistic and linear regression to determine the independent association of BMI on outcomes, adjusted for:\n\nDemographics: Age, sex, race, insurance, residential income, residential region, hospital location/teaching status, and hospital census region.\nMedical History: Atrial fibrillation present.\nComorbidities: Charlson comorbidity index, cancer, coronary artery disease, cerebrovascular disease, heart failure, chronic kidney disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, hyperlipidemia, liver disease, peripheral vascular disease, sleep apnea, valvular heart disease, alcohol use, and smoking status.\n\nSoftware: All analyses were performed using R Version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria)"
  },
  {
    "objectID": "quarto/index.html#baseline-table",
    "href": "quarto/index.html#baseline-table",
    "title": "The Impact of Body Mass Index on Mortality in Patients Hospitalized with Atrial Fibrillation: Insights from the National Inpatient Sample",
    "section": "Baseline Table:",
    "text": "Baseline Table:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 2,714,6751\nNormal weight (BMI 20.0-24.9kg/m²), N = 221,4701\nClass I obesity (BMI 30.0-34.9kg/m²), N = 523,3851\nClass II obesity (BMI 35.0-39.9kg/m²), N = 463,1101\nClass III obesity (BMI ≥40.0kg/m²), N = 925,3951\nOverweight (BMI 25.0-29.9kg/m²), N = 240,4501\nUnderweight (BMI ≤19.9kg/m²), N = 340,8651\np-value2\n\n\n\n\nAge, y\n71 (12)\n78 (11)\n72 (11)\n69 (11)\n66 (11)\n75 (11)\n78 (11)\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Female\n1,339,980 (49%)\n99,405 (45%)\n219,470 (42%)\n210,625 (45%)\n511,675 (55%)\n102,690 (43%)\n196,115 (58%)\n\n\n\n\n    Male\n1,374,625 (51%)\n122,050 (55%)\n303,895 (58%)\n252,485 (55%)\n413,710 (45%)\n137,755 (57%)\n144,730 (42%)\n\n\n\n\nRace\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    White\n2,081,560 (78%)\n168,585 (78%)\n411,310 (80%)\n360,135 (79%)\n699,650 (77%)\n183,850 (78%)\n258,030 (77%)\n\n\n\n\n    Asian or Pacific Islander\n40,625 (1.5%)\n6,270 (2.9%)\n5,775 (1.1%)\n3,765 (0.8%)\n6,600 (0.7%)\n4,475 (1.9%)\n13,740 (4.1%)\n\n\n\n\n    Black\n319,255 (12%)\n22,925 (11%)\n51,200 (10.0%)\n51,875 (11%)\n130,355 (14%)\n24,640 (10%)\n38,260 (11%)\n\n\n\n\n    Hispanic\n153,565 (5.8%)\n13,015 (6.0%)\n32,825 (6.4%)\n27,465 (6.1%)\n48,390 (5.4%)\n16,345 (6.9%)\n15,525 (4.6%)\n\n\n\n\n    Native American\n10,525 (0.4%)\n600 (0.3%)\n1,915 (0.4%)\n1,745 (0.4%)\n4,445 (0.5%)\n690 (0.3%)\n1,130 (0.3%)\n\n\n\n\n    Other\n49,990 (1.9%)\n4,880 (2.3%)\n9,440 (1.8%)\n8,100 (1.8%)\n15,045 (1.7%)\n5,290 (2.2%)\n7,235 (2.2%)\n\n\n\n\nCharlson comorbidity index\n3.40 (2.27)\n3.54 (2.37)\n3.30 (2.29)\n3.33 (2.26)\n3.48 (2.19)\n3.51 (2.37)\n3.27 (2.26)\n&lt;0.001\n\n\nHealthcare insurance\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Private\n463,980 (17%)\n21,460 (9.7%)\n92,785 (18%)\n94,165 (20%)\n195,460 (21%)\n30,680 (13%)\n29,430 (8.6%)\n\n\n\n\n    Medicaid\n188,575 (7.0%)\n9,250 (4.2%)\n28,595 (5.5%)\n30,785 (6.7%)\n92,840 (10%)\n11,540 (4.8%)\n15,565 (4.6%)\n\n\n\n\n    Medicare\n2,004,810 (74%)\n186,415 (84%)\n390,525 (75%)\n327,250 (71%)\n617,295 (67%)\n193,165 (80%)\n290,160 (85%)\n\n\n\n\n    Other\n55,335 (2.0%)\n4,235 (1.9%)\n11,145 (2.1%)\n10,585 (2.3%)\n18,950 (2.0%)\n4,920 (2.0%)\n5,500 (1.6%)\n\n\n\n\nResidential income\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    $1 - $51,999\n770,925 (29%)\n57,435 (26%)\n139,920 (27%)\n129,920 (28%)\n287,285 (31%)\n64,290 (27%)\n92,075 (27%)\n\n\n\n\n    $52,000 - $65,999\n746,850 (28%)\n56,205 (26%)\n142,430 (28%)\n130,145 (29%)\n267,905 (29%)\n63,710 (27%)\n86,455 (26%)\n\n\n\n\n    $66,000 - $87,999\n653,440 (24%)\n52,820 (24%)\n130,875 (25%)\n112,855 (25%)\n218,500 (24%)\n58,595 (25%)\n79,795 (24%)\n\n\n\n\n    $88,000 or more\n504,760 (19%)\n51,775 (24%)\n102,870 (20%)\n83,460 (18%)\n138,660 (15%)\n50,550 (21%)\n77,445 (23%)\n\n\n\n\nResidential region\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Large metro\n1,386,225 (51%)\n123,920 (56%)\n271,340 (52%)\n231,325 (50%)\n442,350 (48%)\n131,255 (55%)\n186,035 (55%)\n\n\n\n\n    Micropolitan\n467,390 (17%)\n32,990 (15%)\n88,440 (17%)\n82,505 (18%)\n176,670 (19%)\n36,170 (15%)\n50,615 (15%)\n\n\n\n\n    Small metro\n854,025 (32%)\n63,800 (29%)\n162,370 (31%)\n148,245 (32%)\n304,305 (33%)\n72,135 (30%)\n103,170 (30%)\n\n\n\n\nHospital location/teaching status\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Rural\n228,895 (8.4%)\n16,960 (7.7%)\n38,745 (7.4%)\n38,195 (8.2%)\n88,975 (9.6%)\n17,220 (7.2%)\n28,800 (8.4%)\n\n\n\n\n    Urban, non-teaching\n521,570 (19%)\n43,970 (20%)\n97,470 (19%)\n90,640 (20%)\n178,170 (19%)\n45,405 (19%)\n65,915 (19%)\n\n\n\n\n    Urban, teaching\n1,964,210 (72%)\n160,540 (72%)\n387,170 (74%)\n334,275 (72%)\n658,250 (71%)\n177,825 (74%)\n246,150 (72%)\n\n\n\n\nHospital census region\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n&lt;0.001\n\n\n    Midwest\n773,245 (28%)\n61,240 (28%)\n156,910 (30%)\n137,430 (30%)\n272,605 (29%)\n64,755 (27%)\n80,305 (24%)\n\n\n\n\n    Northeast\n487,530 (18%)\n41,585 (19%)\n89,500 (17%)\n79,260 (17%)\n164,900 (18%)\n43,990 (18%)\n68,295 (20%)\n\n\n\n\n    South\n1,018,790 (38%)\n78,775 (36%)\n196,800 (38%)\n173,845 (38%)\n349,565 (38%)\n92,240 (38%)\n127,565 (37%)\n\n\n\n\n    West\n435,110 (16%)\n39,870 (18%)\n80,175 (15%)\n72,575 (16%)\n138,325 (15%)\n39,465 (16%)\n64,700 (19%)\n\n\n\n\nCancer\n174,670 (6.4%)\n27,360 (12%)\n30,910 (5.9%)\n22,565 (4.9%)\n36,595 (4.0%)\n22,460 (9.3%)\n34,780 (10%)\n&lt;0.001\n\n\nCoronary artery disease\n1,017,110 (37%)\n77,730 (35%)\n231,395 (44%)\n192,880 (42%)\n308,780 (33%)\n98,005 (41%)\n108,320 (32%)\n&lt;0.001\n\n\nCerebrovascular disease\n245,765 (9.1%)\n24,785 (11%)\n53,325 (10%)\n38,900 (8.4%)\n62,985 (6.8%)\n27,280 (11%)\n38,490 (11%)\n&lt;0.001\n\n\nHeart failure\n1,504,445 (55%)\n104,220 (47%)\n271,115 (52%)\n258,590 (56%)\n595,790 (64%)\n119,155 (50%)\n155,575 (46%)\n&lt;0.001\n\n\nChronic kidney disease\n969,520 (36%)\n74,835 (34%)\n186,875 (36%)\n167,510 (36%)\n355,025 (38%)\n87,045 (36%)\n98,230 (29%)\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n1,022,510 (38%)\n68,125 (31%)\n173,435 (33%)\n167,510 (36%)\n397,645 (43%)\n74,515 (31%)\n141,280 (41%)\n&lt;0.001\n\n\nDiabetes mellitus\n1,261,520 (46%)\n60,470 (27%)\n249,715 (48%)\n246,815 (53%)\n542,865 (59%)\n96,215 (40%)\n65,440 (19%)\n&lt;0.001\n\n\nHypertension\n2,341,970 (86%)\n176,150 (80%)\n464,130 (89%)\n415,020 (90%)\n827,120 (89%)\n205,630 (86%)\n253,920 (74%)\n&lt;0.001\n\n\nHyperlipidemia\n1,499,335 (55%)\n103,215 (47%)\n331,660 (63%)\n287,255 (62%)\n500,865 (54%)\n139,645 (58%)\n136,695 (40%)\n&lt;0.001\n\n\nLiver disease\n177,305 (6.5%)\n15,900 (7.2%)\n32,385 (6.2%)\n28,820 (6.2%)\n63,060 (6.8%)\n17,745 (7.4%)\n19,395 (5.7%)\n&lt;0.001\n\n\nPeripheral vascular disease\n370,290 (14%)\n35,150 (16%)\n79,940 (15%)\n64,100 (14%)\n95,930 (10%)\n37,770 (16%)\n57,400 (17%)\n&lt;0.001\n\n\nSleep apnea\n758,150 (28%)\n11,785 (5.3%)\n134,215 (26%)\n168,295 (36%)\n401,140 (43%)\n33,035 (14%)\n9,680 (2.8%)\n&lt;0.001\n\n\nValvular heart disease\n482,535 (18%)\n44,375 (20%)\n106,065 (20%)\n85,750 (19%)\n133,000 (14%)\n49,200 (20%)\n64,145 (19%)\n&lt;0.001\n\n\nAlcohol use\n104,045 (3.8%)\n9,850 (4.4%)\n22,735 (4.3%)\n18,495 (4.0%)\n24,515 (2.6%)\n11,765 (4.9%)\n16,685 (4.9%)\n&lt;0.001\n\n\nSmoking status\n301,510 (11%)\n24,090 (11%)\n58,015 (11%)\n50,390 (11%)\n91,825 (9.9%)\n24,530 (10%)\n52,660 (15%)\n&lt;0.001\n\n\n\n1 Mean (SD); n (%)\n\n\n2 Wilcoxon rank-sum test for complex survey samples; chi-squared test with Rao & Scott’s second-order correction"
  },
  {
    "objectID": "quarto/index.html#outcomes-table",
    "href": "quarto/index.html#outcomes-table",
    "title": "The Impact of Body Mass Index on Mortality in Patients Hospitalized with Atrial Fibrillation: Insights from the National Inpatient Sample",
    "section": "Outcomes Table:",
    "text": "Outcomes Table:\n\n\n\n\n\n\n\n\nCharacteristic\nOverall, N = 2,714,6751\nNormal weight (BMI 20.0-24.9kg/m²), N = 221,4701\nClass I obesity (BMI 30.0-34.9kg/m²), N = 523,3851\nClass II obesity (BMI 35.0-39.9kg/m²), N = 463,1101\nClass III obesity (BMI ≥40.0kg/m²), N = 925,3951\nOverweight (BMI 25.0-29.9kg/m²), N = 240,4501\nUnderweight (BMI ≤19.9kg/m²), N = 340,8651\np-value2\n\n\n\n\nDied during hospitalization\n127,635 (4.7%)\n16,685 (7.5%)\n15,480 (3.0%)\n12,915 (2.8%)\n37,040 (4.0%)\n12,450 (5.2%)\n33,065 (9.7%)\n&lt;0.001\n\n\nLength of stay (days)\n5.0 (3.0, 8.0)\n6.0 (3.0, 10.0)\n4.0 (2.0, 7.0)\n4.0 (2.0, 7.0)\n5.0 (3.0, 8.0)\n5.0 (3.0, 9.0)\n6.0 (3.0, 9.0)\n&lt;0.001\n\n\nInflation-adjusted total charge ($)\n48,531 (26,085, 95,770)\n53,328 (29,199, 102,332)\n48,760 (25,664, 98,371)\n46,557 (24,942, 92,047)\n46,356 (25,277, 91,465)\n53,862 (28,325, 106,550)\n50,424 (27,455, 96,636)\n&lt;0.001\n\n\n\n1 n (%); Median (IQR)\n\n\n2 chi-squared test with Rao & Scott’s second-order correction; Wilcoxon rank-sum test for complex survey samples"
  },
  {
    "objectID": "quarto/index.html#multivariable-logistic-regression",
    "href": "quarto/index.html#multivariable-logistic-regression",
    "title": "The Impact of Body Mass Index on Mortality in Patients Hospitalized with Atrial Fibrillation: Insights from the National Inpatient Sample",
    "section": "Multivariable Logistic Regression:",
    "text": "Multivariable Logistic Regression:\n\nAll-Cause Mortality:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOR1\n95% CI1\np-value\n\n\n\n\nBody mass index\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n0.55\n0.52, 0.58\n&lt;0.001\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n0.57\n0.54, 0.61\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n0.86\n0.82, 0.91\n&lt;0.001\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n0.79\n0.75, 0.84\n&lt;0.001\n\n\n    Underweight (BMI ≤19.9kg/m²)\n1.35\n1.29, 1.42\n&lt;0.001\n\n\nAge, y\n1.02\n1.02, 1.03\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n1.16\n1.13, 1.19\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.32\n1.22, 1.44\n&lt;0.001\n\n\n    Black\n1.10\n1.05, 1.15\n&lt;0.001\n\n\n    Hispanic\n1.22\n1.15, 1.29\n&lt;0.001\n\n\n    Native American\n1.21\n0.98, 1.49\n0.080\n\n\n    Other\n1.21\n1.10, 1.33\n&lt;0.001\n\n\nCharlson comorbidity index\n1.13\n1.12, 1.14\n&lt;0.001\n\n\nHealthcare insurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n1.02\n0.96, 1.09\n0.5\n\n\n    Medicare\n0.86\n0.82, 0.90\n&lt;0.001\n\n\n    Other\n1.47\n1.33, 1.62\n&lt;0.001\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n0.95\n0.92, 0.99\n0.016\n\n\n    $66,000 - $87,999\n0.89\n0.85, 0.93\n&lt;0.001\n\n\n    $88,000 or more\n0.91\n0.87, 0.95\n&lt;0.001\n\n\nResidential region\n\n\n\n\n\n\n\n\n    Large metro\n—\n—\n\n\n\n\n    Micropolitan\n1.19\n1.13, 1.26\n&lt;0.001\n\n\n    Small metro\n1.04\n1.00, 1.08\n0.064\n\n\nHospital location/teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n1.32\n1.22, 1.44\n&lt;0.001\n\n\n    Urban, teaching\n1.43\n1.32, 1.54\n&lt;0.001\n\n\nHospital census region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.97\n0.92, 1.03\n0.3\n\n\n    South\n0.94\n0.90, 0.98\n0.008\n\n\n    West\n1.05\n1.0, 1.10\n0.080\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.06\n1.01, 1.11\n0.011\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.83\n0.81, 0.86\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.21\n1.15, 1.26\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1.15\n1.12, 1.19\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.97\n0.94, 1.00\n0.093\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.95\n0.93, 0.98\n0.002\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.84\n0.82, 0.87\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.68\n0.66, 0.71\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.69\n0.67, 0.71\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2.54\n2.44, 2.65\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.88\n0.84, 0.91\n&lt;0.001\n\n\nSleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.60\n0.58, 0.63\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.85\n0.82, 0.88\n&lt;0.001\n\n\nAlcohol use\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.75\n0.70, 0.81\n&lt;0.001\n\n\nSmoking status\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.79\n0.75, 0.83\n&lt;0.001\n\n\n\n1 OR = Odds Ratio, CI = Confidence Interval"
  },
  {
    "objectID": "quarto/index.html#multivariable-linear-regression",
    "href": "quarto/index.html#multivariable-linear-regression",
    "title": "The Impact of Body Mass Index on Mortality in Patients Hospitalized with Atrial Fibrillation: Insights from the National Inpatient Sample",
    "section": "Multivariable Linear Regression:",
    "text": "Multivariable Linear Regression:\n\nLength of Stay:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nBody mass index\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n-1.7\n-1.8, -1.6\n&lt;0.001\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n-1.9\n-2.0, -1.8\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n-1.1\n-1.2, -1.0\n&lt;0.001\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n-0.65\n-0.76, -0.54\n&lt;0.001\n\n\n    Underweight (BMI ≤19.9kg/m²)\n-0.22\n-0.33, -0.11\n&lt;0.001\n\n\nAge, y\n-0.02\n-0.02, -0.02\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n0.18\n0.14, 0.22\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n1.1\n0.76, 1.4\n&lt;0.001\n\n\n    Black\n0.48\n0.40, 0.57\n&lt;0.001\n\n\n    Hispanic\n0.35\n0.23, 0.47\n&lt;0.001\n\n\n    Native American\n-0.03\n-0.39, 0.34\n0.9\n\n\n    Other\n0.63\n0.42, 0.85\n&lt;0.001\n\n\nCharlson comorbidity index\n0.25\n0.24, 0.27\n&lt;0.001\n\n\nHealthcare insurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n0.65\n0.53, 0.77\n&lt;0.001\n\n\n    Medicare\n0.13\n0.05, 0.20\n&lt;0.001\n\n\n    Other\n0.20\n0.02, 0.38\n0.031\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-0.12\n-0.19, -0.06\n&lt;0.001\n\n\n    $66,000 - $87,999\n-0.19\n-0.26, -0.12\n&lt;0.001\n\n\n    $88,000 or more\n-0.21\n-0.30, -0.12\n&lt;0.001\n\n\nResidential region\n\n\n\n\n\n\n\n\n    Large metro\n—\n—\n\n\n\n\n    Micropolitan\n0.30\n0.19, 0.41\n&lt;0.001\n\n\n    Small metro\n-0.14\n-0.22, -0.06\n&lt;0.001\n\n\nHospital location/teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n0.93\n0.79, 1.1\n&lt;0.001\n\n\n    Urban, teaching\n1.7\n1.6, 1.8\n&lt;0.001\n\n\nHospital census region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n0.24\n0.09, 0.39\n0.002\n\n\n    South\n0.23\n0.11, 0.35\n&lt;0.001\n\n\n    West\n-0.27\n-0.40, -0.14\n&lt;0.001\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.80\n0.69, 0.91\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.25\n-0.29, -0.20\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.99\n0.91, 1.1\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.50\n0.45, 0.54\n&lt;0.001\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.17\n0.10, 0.23\n&lt;0.001\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.09\n-0.14, -0.04\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.09\n-0.14, -0.04\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.55\n-0.62, -0.48\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.76\n-0.80, -0.71\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.93\n0.82, 1.0\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.18\n-0.25, -0.11\n&lt;0.001\n\n\nSleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.83\n-0.87, -0.78\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.24\n0.18, 0.29\n&lt;0.001\n\n\nAlcohol use\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n0.44\n0.31, 0.57\n&lt;0.001\n\n\nSmoking status\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-0.51\n-0.58, -0.44\n&lt;0.001\n\n\n\n1 CI = Confidence Interval\n\n\n\n\n\n\n\n\n\n\nInflation Adjusted Total Charge:\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nBeta\n95% CI1\np-value\n\n\n\n\nBody mass index\n\n\n\n\n\n\n\n\n    Normal weight (BMI 20.0-24.9kg/m²)\n—\n—\n\n\n\n\n    Class I obesity (BMI 30.0-34.9kg/m²)\n-4,366\n-6,307, -2,425\n&lt;0.001\n\n\n    Class II obesity (BMI 35.0-39.9kg/m²)\n-7,746\n-9,812, -5,680\n&lt;0.001\n\n\n    Class III obesity (BMI ≥40.0kg/m²)\n-4,838\n-7,155, -2,521\n&lt;0.001\n\n\n    Overweight (BMI 25.0-29.9kg/m²)\n2,381\n334, 4,429\n0.023\n\n\n    Underweight (BMI ≤19.9kg/m²)\n-848\n-2,905, 1,210\n0.4\n\n\nAge, y\n-886\n-955, -816\n&lt;0.001\n\n\nSex\n\n\n\n\n\n\n\n\n    Female\n—\n—\n\n\n\n\n    Male\n7,505\n6,758, 8,252\n&lt;0.001\n\n\nRace\n\n\n\n\n\n\n\n\n    White\n—\n—\n\n\n\n\n    Asian or Pacific Islander\n19,926\n14,232, 25,621\n&lt;0.001\n\n\n    Black\n-347\n-2,233, 1,538\n0.7\n\n\n    Hispanic\n19,516\n16,254, 22,779\n&lt;0.001\n\n\n    Native American\n-11,706\n-18,156, -5,256\n&lt;0.001\n\n\n    Other\n25,383\n19,095, 31,671\n&lt;0.001\n\n\nCharlson comorbidity index\n1,824\n1,522, 2,127\n&lt;0.001\n\n\nHealthcare insurance\n\n\n\n\n\n\n\n\n    Private\n—\n—\n\n\n\n\n    Medicaid\n-4,472\n-6,806, -2,138\n&lt;0.001\n\n\n    Medicare\n-1,670\n-3,070, -271\n0.019\n\n\n    Other\n1,098\n-2,519, 4,715\n0.6\n\n\nResidential income\n\n\n\n\n\n\n\n\n    $1 - $51,999\n—\n—\n\n\n\n\n    $52,000 - $65,999\n-314\n-1,675, 1,047\n0.7\n\n\n    $66,000 - $87,999\n-2,823\n-4,463, -1,183\n&lt;0.001\n\n\n    $88,000 or more\n-227\n-2,738, 2,284\n0.9\n\n\nResidential region\n\n\n\n\n\n\n\n\n    Large metro\n—\n—\n\n\n\n\n    Micropolitan\n1,556\n-1,075, 4,187\n0.2\n\n\n    Small metro\n-9,681\n-11,994, -7,368\n&lt;0.001\n\n\nHospital location/teaching status\n\n\n\n\n\n\n\n\n    Rural\n—\n—\n\n\n\n\n    Urban, non-teaching\n30,410\n27,442, 33,379\n&lt;0.001\n\n\n    Urban, teaching\n43,830\n41,039, 46,622\n&lt;0.001\n\n\nHospital census region\n\n\n\n\n\n\n\n\n    Midwest\n—\n—\n\n\n\n\n    Northeast\n11,316\n7,229, 15,403\n&lt;0.001\n\n\n    South\n15,311\n12,542, 18,081\n&lt;0.001\n\n\n    West\n41,922\n37,392, 46,451\n&lt;0.001\n\n\nCancer\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n14,435\n12,435, 16,436\n&lt;0.001\n\n\nCoronary artery disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n7,347\n6,514, 8,180\n&lt;0.001\n\n\nCerebrovascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n15,057\n13,514, 16,599\n&lt;0.001\n\n\nHeart failure\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n1,346\n423, 2,269\n0.004\n\n\nChronic kidney disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1,702\n-2,816, -589\n0.003\n\n\nChronic obstructive pulmonary disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-2,704\n-3,545, -1,864\n&lt;0.001\n\n\nDiabetes mellitus\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-1,893\n-2,784, -1,003\n&lt;0.001\n\n\nHypertension\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-8,356\n-9,673, -7,039\n&lt;0.001\n\n\nHyperlipidemia\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-5,456\n-6,313, -4,600\n&lt;0.001\n\n\nLiver disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n21,222\n18,914, 23,530\n&lt;0.001\n\n\nPeripheral vascular disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n2,773\n1,293, 4,254\n&lt;0.001\n\n\nSleep apnea\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-11,691\n-12,608, -10,774\n&lt;0.001\n\n\nValvular heart disease\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n15,003\n13,725, 16,282\n&lt;0.001\n\n\nAlcohol use\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-8,389\n-10,529, -6,249\n&lt;0.001\n\n\nSmoking status\n\n\n\n\n\n\n\n\n    No\n—\n—\n\n\n\n\n    Yes\n-6,981\n-8,249, -5,713\n&lt;0.001\n\n\n\n1 CI = Confidence Interval"
  }
]